• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Walgreens Boots Alliance Inc.

    7/12/24 4:42:05 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $WBA alert in real time by email
    8-K
    false 0001618921 --08-31 0001618921 2024-07-10 2024-07-10 0001618921 us-gaap:CommonStockMember 2024-07-10 2024-07-10 0001618921 wba:M3.600WalgreensBootsAllianceInc.NotesDue2025Member 2024-07-10 2024-07-10 0001618921 wba:M2.125WalgreensBootsAllianceInc.NotesDue2026Member 2024-07-10 2024-07-10

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): July 10, 2024

     

     

    WALGREENS BOOTS ALLIANCE, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-36759   47-1758322

    (State or other jurisdiction

    of incorporation)

      (Commission File
    Number)
     

    (IRS Employer

    Identification Number)

     

    108 Wilmot Road, Deerfield, Illinois   60015
    (Address of principal executive offices)   (Zip Code)

    Registrant’s telephone number, including area code: (847) 315-2500

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

      ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

      ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

      ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

      ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, $0.01 par value   WBA   The Nasdaq Stock Market LLC
    3.600% Walgreens Boots Alliance, Inc. notes due 2025   WBA25   The Nasdaq Stock Market LLC
    2.125% Walgreens Boots Alliance, Inc. notes due 2026   WBA26   The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 5.03.

    Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

    On July 10, 2024, the Board of Directors (the “Board”) of Walgreens Boots Alliance, Inc. (the “Company”) approved and adopted, effective immediately, the Company’s Amended and Restated Bylaws (as amended and restated, the “Bylaws”). The amendments to the Bylaws, among other things:

     

      •  

    Modify the Bylaws to more closely align to the Delaware General Corporation Law (the “DGCL”) and the Certificate of Incorporation of the Company (the “Certificate of Incorporation”), including provisions related to meetings held by remote communications, accessing the stockholder list, various notice requirements, procedures for stockholder action by consent and requesting special meetings, Board and committee quorums, Board action by consent, signing stock certificates, Board approval of Bylaw amendments and indemnification of directors and officers.

     

      •  

    Clarify and update certain procedural requirements in the advance notice provisions relating to the requirements for stockholder-submitted nominations and/or other business proposals, including, among other things, to no longer require stockholder nominees to interview with the Board, to require a proposing stockholder to represent that it or its qualified representative will appear at the stockholder meeting to present its nomination or proposal and whether it intends to deliver proxy materials or solicit proxies and votes in support of its nomination or proposal, and to clarify the Company’s deadline for delivering a director questionnaire following a proper request.

     

      •  

    Update the advance notice provisions to require the notice from stockholders to include certain information from stockholders or beneficial owners that are entities, to remove the requirements for the notice from stockholders to include information from persons “acting in concert,” “affiliates,” and “associates” and to remove the requirement for the notice from stockholders to disclose information about certain performance related fees.

     

      •  

    Update certain procedural requirements for director nominations by stockholders under the advance notice provision, including to require reasonable documentary evidence of compliance with Rule 14a-19, clarify the timing for providing notice of additional or substitute nominations, and limit the number of stockholder nominees to the number of directors to be elected.

     

      •  

    Revise certain requirements related to stockholder meetings, including: clarifying what constitutes a “contested election” and the existing voting standard in uncontested director elections, revising the default location for stockholder meetings, removing limitations on voting certain shares registered in the name of another entity, person or receiver and removing the requirement that an incumbent director offer to resign following an uncontested election in which the director did not receive support from a majority of votes cast (which provision is set forth in the Company’s Corporate Governance Guidelines), clarifying that, with respect to matters that are submitted to the stockholders, if a different or minimum vote is required by the Certificate of Incorporation, the Bylaws, the rules and regulations of any stock exchange applicable to the Company, or any law or regulation applicable to the Company or its securities, such different or minimum vote shall be the applicable vote on the matter, and addressing the procedures for adjourning and designating the chair of stockholder meetings.

     

      •  

    Modify certain other provisions, including related to the registered agent, removing language stating that certain actions are not conflicts of interests in order to default to the DGCL, the appointment of committee members, the list of required Company officers, and changes to the Company’s fiscal year.

    In addition, certain other technical, ministerial, clarifying and conforming changes were made to the Bylaws. The foregoing description of the amendments to the Company’s Bylaws is qualified in all respects by reference to the text of the Bylaws, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.


    Item 9.01

    Financial Statements and Exhibits.

    The following exhibits are included herewith:

     

    Exhibit    Description
    3.1    Amended and Restated Bylaws of Walgreens Boots Alliance, Inc.
    104    Cover Page Interactive Data File (formatted as inline XBRL)


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        WALGREENS BOOTS ALLIANCE, INC.
    Date: July 12, 2024     By:  

    /s/ Joseph B. Amsbary Jr.

        Name:   Joseph B. Amsbary Jr.
        Title:   Senior Vice President, Corporate Secretary
    Get the next $WBA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WBA

    DatePrice TargetRatingAnalyst
    2/28/2025$11.00 → $9.00Hold → Sell
    Deutsche Bank
    2/26/2024$23.00Market Perform
    Leerink Partners
    2/20/2024Hold → Reduce
    HSBC Securities
    1/3/2024$21.00Underweight
    Barclays
    12/22/2023$27.00Hold
    HSBC Securities
    10/23/2023$27.00 → $30.00Neutral → Overweight
    JP Morgan
    7/3/2023$37.00 → $27.00Underweight
    Morgan Stanley
    6/28/2023$46.00 → $34.00Buy → Hold
    Deutsche Bank
    More analyst ratings

    $WBA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    September 12, 2023 - FDA Issues Warning Letters to Firms Marketing Unapproved Eye Products

    For Immediate Release: September 12, 2023 The U.S. Food and Drug Administration has issued warning letters to eight companies for manufacturing or marketing unapproved ophthalmic drug products in violation of federal law. These warning letters are part of the agency’s ongoing effort to protect Americans from potentially harmful ophthalmic products. Eye products addressed in the eight warning letters are illegal

    9/12/23 10:44:21 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $WBA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Walgreen Co. To Operate as Private Standalone Company Following Acquisition By Sycamore Partners

    Appoints Mike Motz as Chief Executive Officer Walgreen Co. ("Walgreens", or the "Company"), America's leading independent retail pharmacy, announced today that it is now operating as a private standalone company following its acquisition by Sycamore Partners ("Sycamore"), a leading private equity firm based in New York. Sycamore is acquiring the business in partnership with Stefano Pessina and his family, who have reinvested 100% of their interests in Walgreens, demonstrating their ongoing support and confidence in the Company's future. Mike Motz has been appointed as Chief Executive Officer of Walgreens effective immediately. Motz was formerly CEO of Staples US Retail, a Sycamore por

    8/28/25 8:31:00 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Sycamore Partners Completes Acquisition of Walgreens Boots Alliance

    Sycamore Partners ("Sycamore") announced today that it has completed its acquisition of Walgreens Boots Alliance, Inc. (the "Company" or "WBA"). Sycamore is acquiring the business in partnership with Stefano Pessina and his family, who have reinvested 100% of their interests in WBA, demonstrating their ongoing support and confidence in the Company's future. Stefan Kaluzny, Managing Director of Sycamore, said, "Walgreens Boots Alliance, Inc., its companies and its dedicated team members play an essential role in the communities they serve around the world. We look forward to partnering with the management teams at each company, including Walgreens, The Boots Group, Shields Health Solutio

    8/28/25 8:30:00 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Blazing Star Merger Sub, Inc. announces final results for the previously announced Tender Offer and Consent Solicitation for any and all Walgreens Boots Alliance, Inc.'s 3.600% senior notes due 2025, 2.125% senior notes due 2026, 3.450% notes due 2026, 8.125% notes due 2029, 3.200% Notes due 2030, 4.500% senior notes due 2034, 4.800% senior notes due 2044, 4.650% notes due 2046 and 4.100% Notes due 2050, and any and all of Walgreen Co.'s 4.400% notes due 2042

    NEW YORK, Aug. 27, 2025 /PRNewswire/ -- Blazing Star Merger Sub, Inc. (the "Offeror" announced today the final results as of 5:00 p.m. (New York City time) on August 27, 2025 (the "Expiration Time"), for the previously announced cash tender offers (each, an "Offer" and, collectively, the "Tender Offer") for any and all of Walgreens Boots Alliance, Inc.'s (NASDAQ:WBA) ("WBA") outstanding (1) 3.600% senior notes due 2025 (the "2025 Notes"), (2) 2.125% senior notes due 2026 (the "2.125% 2026 Notes"), (3) 3.450% notes due 2026 (the "3.450% 2026 Notes"), (4) 8.125% notes due 2029 (the "2029 Notes"), (5) 3.200% notes due 2030 (the "2030 Notes"), (6) 4.500% senior notes due 2034 (the "2034 Notes"),

    8/27/25 7:10:00 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $WBA
    SEC Filings

    View All

    SEC Form 15-12G filed by Walgreens Boots Alliance Inc.

    15-12G - Walgreens Boots Alliance, Inc. (0001618921) (Filer)

    9/8/25 1:00:15 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form SCHEDULE 13G filed by Walgreens Boots Alliance Inc.

    SCHEDULE 13G - Walgreens Boots Alliance, Inc. (0001618921) (Subject)

    9/4/25 5:30:45 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form S-8 POS filed by Walgreens Boots Alliance Inc.

    S-8 POS - Walgreens Boots Alliance, Inc. (0001618921) (Filer)

    8/28/25 3:46:00 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $WBA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Chairman of Board Pessina Stefano sold $9,163,161 worth of shares (832,258 units at $11.01) and bought $9,163,161 worth of shares (832,258 units at $11.01), decreasing direct ownership by 56% to 657,308 units (SEC Form 4)

    4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

    4/29/25 8:49:21 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Bhandari Inderpal S bought $54,150 worth of shares (3,000 units at $18.05) (SEC Form 4)

    4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

    4/15/24 5:45:26 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Mahajan Manmohan bought $116,280 worth of shares (6,000 units at $19.38) (SEC Form 4)

    4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

    4/2/24 6:40:23 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $WBA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP Chief Corp Affairs Officer Fabbri Beth Amber L. returned 124,670 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

    8/28/25 3:27:11 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    EVP and Global CFO Mahajan Manmohan returned 414,273 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

    8/28/25 3:26:55 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    EVP, Global CLO & Corp. Sec. Minnix Lanesha returned 348,093 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

    8/28/25 3:26:30 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $WBA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Walgreens Boots Alliance downgraded by Deutsche Bank with a new price target

    Deutsche Bank downgraded Walgreens Boots Alliance from Hold to Sell and set a new price target of $9.00 from $11.00 previously

    2/28/25 7:36:45 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Leerink Partners initiated coverage on Walgreens Boots Alliance with a new price target

    Leerink Partners initiated coverage of Walgreens Boots Alliance with a rating of Market Perform and set a new price target of $23.00

    2/26/24 8:28:07 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Walgreens Boots Alliance downgraded by HSBC Securities

    HSBC Securities downgraded Walgreens Boots Alliance from Hold to Reduce

    2/20/24 10:23:30 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $WBA
    Leadership Updates

    Live Leadership Updates

    View All

    Walgreen Co. To Operate as Private Standalone Company Following Acquisition By Sycamore Partners

    Appoints Mike Motz as Chief Executive Officer Walgreen Co. ("Walgreens", or the "Company"), America's leading independent retail pharmacy, announced today that it is now operating as a private standalone company following its acquisition by Sycamore Partners ("Sycamore"), a leading private equity firm based in New York. Sycamore is acquiring the business in partnership with Stefano Pessina and his family, who have reinvested 100% of their interests in Walgreens, demonstrating their ongoing support and confidence in the Company's future. Mike Motz has been appointed as Chief Executive Officer of Walgreens effective immediately. Motz was formerly CEO of Staples US Retail, a Sycamore por

    8/28/25 8:31:00 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Interactive Brokers Group Set to Join S&P 500, Talen Energy to Join S&P MidCap 400 and Kinetik Holdings to Join S&P SmallCap 600

    NEW YORK, Aug. 25, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600: S&P MidCap 400 constituent Interactive Brokers Group Inc. (NASD: IBKR) will replace Walgreens Boots Alliance Inc. (NASD: WBA) in the S&P 500, and Talen Energy Corp. (NASD: TLN) will replace Interactive Brokers Group in the S&P MidCap 400 effective prior to the opening of trading on Thursday, August 28. Sycamore Partners is acquiring Walgreens Boots Alliance in a deal expected to be completed soon, pending final closing conditions.  Kinetik Holdings Inc. (NYSE:KNTK) will replace Pacific Premier Bancorp Inc. (NASD: PPBI) in the S&P SmallCap 600 ef

    8/25/25 5:41:00 PM ET
    $COLB
    $IBKR
    $KNTK
    Major Banks
    Finance
    Investment Bankers/Brokers/Service
    Natural Gas Distribution

    Walgreens Appoints Jason Stenta as SVP and Chief Commercial Officer

    Stenta will lead B2B commercial growth strategy as the company strengthens its role as the first choice for community pharmacy and health services in the U.S. Walgreens, an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, today announced the appointment of Jason Stenta as SVP and chief commercial officer. In this new role, Stenta will lead the company's commercial growth strategy, driving development and commercialization of B2B healthcare services built on the company's core assets, and enhancing partnerships with payers, health system providers and life sciences companies. This press release features multimedia. View the full release

    10/7/24 8:00:00 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $WBA
    Financials

    Live finance-specific insights

    View All

    Walgreens Boots Alliance Shareholders Overwhelmingly Approve Transaction with Sycamore Partners

    Transaction expected to close in the third or fourth quarter of calendar year 2025 Walgreens Boots Alliance, Inc. (NASDAQ:WBA) (the "Company" or "WBA") today announced that at the Company's Special Meeting of Shareholders (the "Special Meeting"), WBA shareholders approved the previously announced acquisition of the Company by entities affiliated with Sycamore Partners Management, L.P. ("Sycamore"). According to the preliminary results, approximately 96% of votes cast at the Special Meeting by all shareholders were voted in favor of the merger agreement proposal. In addition, approximately 95% of the votes cast at the Special Meeting by unaffiliated shareholders were voted in favor of th

    7/11/25 9:59:00 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Walgreens Boots Alliance Reports Fiscal 2025 Third Quarter Results

    Third quarter financial results Third quarter loss per share1 was $0.20 compared to earnings per share of $0.40 in the year-ago quarter. The decline in earnings per share was primarily driven by prior year after-tax gains related to fair value adjustments on variable prepaid forward derivatives and a partial sale of the Company's equity method investment in Cencora, and higher tax expense in the current quarter. Adjusted earnings per share (EPS)2 was $0.38 compared to adjusted EPS2 of $0.63 in the year-ago quarter. The decline in adjusted EPS2 was primarily driven by a higher adjusted effective tax rate2, higher incentive accruals, lower U.S. retail sales and lower equity earnings in

    6/26/25 7:00:00 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Walgreens Boots Alliance Reports Fiscal 2025 Second Quarter Results

    Second quarter financial results Second quarter loss per share1 was $3.30 compared to loss per share of $6.85 in the year-ago quarter. Second quarter results include $4.2 billion of non-cash impairment charges attributable to WBA, net of tax and non-controlling interest, related to goodwill, intangible and other long-lived assets primarily at U.S. Retail Pharmacy and VillageMD, and $1.0 billion of after-tax gains related to asset monetization activities. Adjusted earnings per share (EPS)2 was $0.63 compared to adjusted EPS2 of $1.20 in the year-ago quarter. The decline in adjusted EPS2 was primarily driven by prior year adjusted effective tax benefit2, lower U.S. retail sales and prior

    4/8/25 7:00:00 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $WBA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Walgreens Boots Alliance Inc.

    SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)

    10/18/24 12:45:41 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Amendment: SEC Form SC 13D/A filed by Walgreens Boots Alliance Inc.

    SC 13D/A - Walgreens Boots Alliance, Inc. (0001618921) (Filed by)

    8/20/24 4:05:58 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form SC 13G/A filed by Walgreens Boots Alliance Inc. (Amendment)

    SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)

    2/13/24 5:17:30 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples